Takafumi Yanagisawa

1 month ago | acsjournals.onlinelibrary.wiley.com | Wataru Fukuokaya |Keiichiro Mori |Takafumi Yanagisawa |Fumihiko Urabe |Pawel Rajwa |Alberto Briganti | +4 more

Sep 12, 2024 | nature.com | Akihiro Matsukawa |Takafumi Yanagisawa |Marcin Miszczyk |Ichiro Tsuboi |Ekaterina Laukhtina |Juan Rivas | +4 more

AbstractRecent advancements in the management of biochemical recurrence (BCR) following local treatment for prostate cancer (PCa), including the use of androgen receptor signaling inhibitors (ARSIs), have broadened the spectrum of therapeutic options. We aimed to compare salvage therapies in patients with BCR after definitive local treatment for clinically non-metastatic PCa with curative intent.

Sep 4, 2024 | nature.com | Akihiro Matsukawa |Takafumi Yanagisawa |Ekaterina Laukhtina |Takahiro Kimura |Pawel Rajwa

AbstractAndrogen-receptor pathway inhibitors (ARPIs) have dramatically changed the management of advanced/metastatic prostate cancer (PCa). However, their cardiovascular toxicity remains to be clarified.

Aug 10, 2023 | bjui-journals.onlinelibrary.wiley.com | Ekaterina Laukhtina |Markus von Deimling |Benjamin Pradere |Takafumi Yanagisawa

BCa bladder cancer EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer–Quality of Life Questionnaire–Cancer 30 FSFI Female Sexual Function Index HRQOL health-related quality of life IC ileal conduit ISC intermittent self-catheterization NSRC nerve-sparing radical cystectomy ONB orthotopic neobladder RC radical cystectomy ROBINS-I Risk of bias in non-randomized studies of interventions tool ROPRC reproductive organ-preserving radical cystectomy SF short-form Introduction...